YAQ006 & YAQ007
Hepatic Encephalopathy (HE) recurrence; Urea Cycle Disorders (UCD)
Key Facts
About Yaqrit
Yaqrit is a clinical-stage biotech pioneering a multi-target approach to advanced liver disease, built on foundational research into the gut-liver axis and systemic inflammation. Its diversified pipeline spans small molecules, advanced microbiome therapeutics, and an extracorporeal liver support device, targeting high-unmet-need indications from decompensated cirrhosis to organ failure. With a seasoned leadership team, key industry partnerships, and programs advancing into clinical trials, the company is positioned to address significant gaps in the hepatology treatment landscape. Its strategy involves intervening at different points in the disease's inflammatory cascade to both treat and prevent progression.
View full company profile